158 related articles for article (PubMed ID: 25641180)
1. Adjuvant sorafenib reduced mortality and prolonged overall survival and post-recurrence survival in hepatocellular carcinoma patients after curative resection: a single-center experience.
Zhang W; Zhao G; Wei K; Zhang Q; Ma W; Song T; Wu Q; Zhang T; Kong D; Li Q
Biosci Trends; 2014 Dec; 8(6):333-8. PubMed ID: 25641180
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients.
Xia F; Wu LL; Lau WY; Huan HB; Wen XD; Ma KS; Li XW; Bie P
World J Gastroenterol; 2016 Jun; 22(23):5384-92. PubMed ID: 27340354
[TBL] [Abstract][Full Text] [Related]
3. Hepatocellular carcinoma cases with high levels of c-Raf-1 expression may benefit from postoperative adjuvant sorafenib after hepatic resection even with high risk of recurrence.
Lei J; Zhong J; Hao J; Liu Z; Zhang P; Wu L; Yan L; Zhu J; Zeng Y; Li B; Wen T; Wang W
Oncotarget; 2016 Jul; 7(27):42598-42607. PubMed ID: 26981887
[TBL] [Abstract][Full Text] [Related]
4. Safety of liver resection for hepatocellular carcinoma after sorafenib therapy: a multicenter case-matched study.
Barbier L; Fuks D; Pessaux P; Muscari F; Le Treut YP; Faivre S; Belghiti J
Ann Surg Oncol; 2013 Oct; 20(11):3603-9. PubMed ID: 23715965
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation.
Waghray A; Balci B; El-Gazzaz G; Kim R; Pelley R; Narayanan Menon KV; Estfan B; Romero-Marrero C; Aucejo F
Clin Transplant; 2013; 27(4):555-61. PubMed ID: 23758296
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant sorafenib therapy in patients with resected hepatocellular carcinoma: evaluation of predictive factors.
Zhang W; Zhao G; Wei K; Zhang Q; Ma W; Wu Q; Zhang T; Kong D; Li Q; Song T
Med Oncol; 2015 Apr; 32(4):107. PubMed ID: 25750040
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib as an adjuvant therapy for resectable hepatocellular carcinoma: A single center experience.
Antoniou EA; Margonis GA; Amini N; Anastasiou M; Angelou A; Kim Y; Kouraklis G
J BUON; 2016; 21(5):1189-1194. PubMed ID: 27837622
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study.
Sposito C; Mariani L; Germini A; Flores Reyes M; Bongini M; Grossi G; Bhoori S; Mazzaferro V
J Hepatol; 2013 Jul; 59(1):59-66. PubMed ID: 23500153
[TBL] [Abstract][Full Text] [Related]
9. Recurrence-free survival of a hepatocellular carcinoma patient with tumor thrombosis of the inferior vena cava after treatment with sorafenib and hepatic resection.
Nakamura K; Beppu T; Hayashi H; Okabe H; Imai K; Nitta H; Chikamoto A; Ishiko T; Sasaki M; Baba H
Int Surg; 2015 May; 100(5):908-14. PubMed ID: 26011214
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib treatment for recurrent hepatocellular carcinoma after liver transplantation.
Sotiropoulos GC; Nowak KW; Fouzas I; Vernadakis S; Kykalos S; Klein CG; Paul A
Transplant Proc; 2012 Nov; 44(9):2754-6. PubMed ID: 23146514
[TBL] [Abstract][Full Text] [Related]
11. Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature.
Zavaglia C; Airoldi A; Mancuso A; Vangeli M; Viganò R; Cordone G; Gentiluomo M; Belli LS
Eur J Gastroenterol Hepatol; 2013 Feb; 25(2):180-6. PubMed ID: 23044808
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial.
Xia Y; Qiu Y; Li J; Shi L; Wang K; Xi T; Shen F; Yan Z; Wu M
Ann Surg Oncol; 2010 Dec; 17(12):3137-44. PubMed ID: 20602260
[TBL] [Abstract][Full Text] [Related]
13. Phase I adjuvant trial of sorafenib in patients with hepatocellular carcinoma after orthotopic liver transplantation.
Jia N; Liou I; Halldorson J; Carithers R; Perkins J; Reyes J; Yeh M; Stohr E; Rao S; Lin EH
Anticancer Res; 2013 Jun; 33(6):2797-800. PubMed ID: 23749944
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib delays recurrence and metastasis after liver transplantation in a rat model of hepatocellular carcinoma with high expression of phosphorylated extracellular signal-regulated kinase.
Yan J; Tan C; Gu F; Jiang J; Xu M; Huang X; Dai Z; Wang Z; Fan J; Zhou J
Liver Transpl; 2013 May; 19(5):507-20. PubMed ID: 23408515
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy and safety of sorafenib in the prevention and treatment of hepatocellular carcinoma recurrences after liver transplantation].
Hu AB; He XS; Tai Q; Zhu XF; Ma Y; Wang DP; Wang GD; Wu LW; Ju WQ; Huang JF
Zhonghua Yi Xue Za Zhi; 2012 May; 92(18):1264-7. PubMed ID: 22883065
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy.
Saab S; McTigue M; Finn RS; Busuttil RW
Exp Clin Transplant; 2010 Dec; 8(4):307-13. PubMed ID: 21143097
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib use in the transplant setting.
Castelli G; Burra P; Giacomin A; Vitale A; Senzolo M; Cillo U; Farinati F
Liver Transpl; 2014 Sep; 20(9):1021-8. PubMed ID: 24809799
[TBL] [Abstract][Full Text] [Related]
18. [Safety and efficacy of Sorafenib in treatment of tumor recurrence in liver transplantation recipients].
Li XH; Zhong KB; Liu Y; Yang DH; Zhou J
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Sep; 31(9):1608-10. PubMed ID: 21945779
[TBL] [Abstract][Full Text] [Related]
19. Role of Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation.
de'Angelis N; Landi F; Nencioni M; Palen A; Lahat E; Salloum C; Compagnon P; Lim C; Costentin C; Calderaro J; Luciani A; Feray C; Azoulay D
Prog Transplant; 2016 Dec; 26(4):348-355. PubMed ID: 27555074
[TBL] [Abstract][Full Text] [Related]
20. The Outcome of Sorafenib Therapy on Unresectable Hepatocellular Carcinoma: Experience of Conversion and Salvage Hepatectomy.
Yoshimoto T; Imura S; Morine Y; Ikemoto T; Arakawa Y; Iwahashi S; Saito YU; Takasu C; Ishikawa D; Teraoku H; Bando Y; Shimada M
Anticancer Res; 2018 Jan; 38(1):501-507. PubMed ID: 29277815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
